Logo

Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy

Author(s):
Gian Paolo CavigliaGian Paolo Caviglia1, Maria Lorena AbateMaria Lorena Abate1, Paola ManziniPaola Manzini2, Franca DanielleFranca Danielle2, Alessia CiancioAlessia CiancioAlessia Ciancio ORCID3, Chiara RossoChiara Rosso1, Antonella OliveroAntonella Olivero1, Rinaldo PellicanoRinaldo PellicanoRinaldo Pellicano ORCID3,*, Giovanni Antonio TouscozGiovanni Antonio TouscozGiovanni Antonio Touscoz ORCID3, Antonina SmedileAntonina SmedileAntonina Smedile ORCID3, Mario RizzettoMario RizzettoMario Rizzetto ORCID3
1Department of Internal Medicine, University of Turin, Italy
2Blood Bank, San Giovanni Battista University Hospital (Molinette), Italy
3Department of Gastroenterology and Hepatology, San Giovanni Battista University Hospital (Molinette), rinaldo_pellican@hotmail.com, Italy


Hepatitis Monthly:Vol. 12, issue 11; 7292
Published online:Nov 30, 2012
Article type:Research Article
Received:Jul 01, 2012
Accepted:Jul 28, 2012
How to Cite:Gian Paolo CavigliaMaria Lorena AbatePaola ManziniFranca DanielleAlessia CiancioChiara RossoAntonella OliveroRinaldo PellicanoGiovanni Antonio TouscozAntonina SmedileMario Rizzettoet al.Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy.Hepat Mon.12(11):7292.https://doi.org/10.5812/hepatmon.7292.

Abstract

Background:

Occult hepatitis B virus infection (OBI) is defined as the presence of hepatitis B virus (HBV) DNA in the liver and/or in the serum of patients with negative results of hepatitis B s antigen (HBsAg) test with or without serological markers of previous viral exposure. The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear.

Objectives:

The Aim of this study was to assess OBI prevalence and its potential implications on treatment outcome in a cohort of patients with CHC underwent standard antiviral therapy.

Patients and Methods:

Baseline serum samples from 137 HBsAg-negative CHC patients treated with pegylated-interferon and ribavirin (73 Responders/74 Non Responders),were retrospectively analyzed for HBV status.

Results:

Seventy-three patients (53.3%) showed markers of previous exposure to HBV. HBV DNA was detected in 2 of 137 serum samples (1.5%), both carrying HBV antibodies. Liver biopsies and post-therapy sera were available for 35 patients (12 Responders/23 Non Responders). HBV DNA sequences were found in 13 of 35 specimens (37.1%), all of patients with HBV DNA negativity in basal and post-therapy serum samples. Among OBI-positive patients, 5 (38.5%) carried serological markers of HBV infection. Regarding therapy outcome, in the OBI-positive group there were 5 of 13 (38.5%) sustained virological responders (SVR) compared to 7 of 22 (31.8%) in the OBI-negative one.

Conclusions:

Despite the high prevalence rate of liver HBV DNA in patients with CHC, SVR was not affected by occult HBV infection.

Full Text

Full text is available in PDF

comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles